Prospects for an anti-ghrelin vaccine to treat obesity.
In the battle to treat the pandemic of obesity, one therapeutic strategy is to block endogenous signals that stimulate appetite and control body weight. One such molecule is ghrelin, a gut peptide that is the only known orexigenic hormone and is a likely contributor to mealtime hunger. The relative importance of ghrelin in long-term body-weight regulation (and thus its promise as an anti-obesity target) is uncertain, however, because genetic and pharmacologic blockade of ghrelin signaling have yielded variable results to date. Using a novel approach of vaccinating rats against their own ghrelin, Zorilla et al. report that animals with high ghrelin-specific antibody titers displayed restricted body weight, without evidence of non-specific inflammation following the vaccine. These results favor a meaningful role for ghrelin in energy homeostasis, hinting at a possible new anti-obesity approach. More broadly, the work of Zorilla et al. supports the feasibility of vaccinations directed against specific autologous targets--immunopharmacotherapy that could potentially be developed to target a wide array of medical conditions.
Carlson
Molly J
MJ
Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, VA Puget Sound Health Care System, Seattle, WA 98108, USA. mollyc@u.washington.edu
Cummings
David E
DE
D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001835:Body Weight; D054439:Ghrelin; D006801:Humans; D009765:Obesity / Q000517:prevention & control* / Q000628:therapy*; D036361:Peptide Hormones / Q000037:antagonists & inhibitors* / Q000502:physiology; D051381:Rats; D014612:Vaccines / Q000627:therapeutic use*
D019440:Anti-Obesity Agents; D054439:Ghrelin; D036361:Peptide Hormones; D014612:Vaccines